Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05784129 · ClinicalTrials.gov registry record · Phase 3
A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
A Phase 3 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT05784129 is a Phase 3 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 4 participants.
The verdict
NCT05784129, a Phase 3 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of guselkumab treatment compared with placebo (an inactive substance with no medicine) in preventing recurrence of Crohn's disease in participants after surgery.
Interventions
- DRUG Placebo
- DRUG Guselkumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2023-10-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05784129
The ClinicalTrials.gov registry entry for NCT05784129 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05784129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05784129 about?
NCT05784129 is a clinical study titled "A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection". The purpose of this study is to evaluate the effectiveness of guselkumab treatment compared with placebo (an inactive substance with no medicine) in preventing recurrence of Crohn's disease in participants after surgery.
What is the current status of trial NCT05784129?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2023-02-21. Estimated completion is 2023-10-10.
What interventions are being tested in trial NCT05784129?
The interventions under investigation include: Placebo (DRUG), Guselkumab (DRUG).
Who is sponsoring clinical trial NCT05784129?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.